Research
Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti–PD-1 efficacy in colorectal cancer
Science · By Siqi Chen, Qishan Liu, Shubiao Ye, Jing Yu, Yongxin Xie, Yuhai Yuan, Jianning Song, Yaqing Du, Min Li, Xueli Zhang, Yanping Ma, Zhensen Lin, Yu Zhang, Xin-Yuan Guan, Guiwei He, Chen Jiang, Xiaona Fang, Xiaosheng He, Lei Li, Ping Lan & Qian Yan ·
The Brief
- Published in Science Translational Medicine, Volume 18, Issue 876, November 2026.
- The study reports that an anti-FOLR1 antibody-drug conjugate enhances anti-PD-1 efficacy in colorectal cancer.
- The work is framed as targeting cancer immune evasion.
Why it matters
It suggests that combining a FOLR1-targeted antibody-drug conjugate with PD-1 blockade may improve immunotherapy response in colorectal cancer, which matters for cancer immunology research and drug development.
Who’s affected
- cancer researchers and immunologists
- colorectal cancer clinicians and drug developers
- #cancer immunology
- #colorectal cancer
- #antibody-drug conjugate
- #anti-pd-1
- #immunotherapy
Science Translational Medicine, Volume 18, Issue 876 , November 2026.